Trial
NCT00406419
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genentech, Inc.
Collaborators
Roche Pharma AG
Condition
Rheumatoid Arthritis
Intervention
Methotrexate
Why stopped
Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-27